Overview
BiVACOR is a clinical-stage medical device company developing the BiVACOR Total Artificial Heart (TAH) to replace a failing heart. The device is a compact, titanium implant that uses a single magnetically levitated rotor to pump blood to the lungs and the rest of the body, eliminating valves and mechanical bearings to reduce blood damage. It serves as a bridge-to-transplant and aims to become a long-term (permanent) alternative to heart transplantation. BiVACOR operates in the cardiovascular medtech space, pursuing regulatory approval through preclinical and clinical trials, including an FDA Breakthrough Device Designation and an Early Feasibility Study. Its strategy includes expanding from Australia to the US, securing funding, and advancing toward commercialization to address the large unmet need in end-stage heart failure.
Work here?Claim your company
Simplify's take
What believers are saying
- UCSF transplanted its first artificial-heart patient on March 9, 2026, proving clinical utility.
- BiVACOR’s 2026 expanded EFS adds fourteen patients, speeding safety and performance data.
- MRFF funding and 2025 Breakthrough Designation extend cash runway and accelerate commercialization discussions.
What critics are saying
- Two Australian patients died from intracranial hemorrhage in 2025, exposing anticoagulation fragility.
- BiVACOR remains bridge-to-transplant dependent; any transplant bottleneck traps patients on temporary support.
- If expanded 2026 enrollment stalls, Syncardia and next-generation pumps win the durable-artificial-heart market.
What makes BiVACOR unique
- BiVACOR’s titanium MAGLEV rotor eliminates valves and bearings, reducing wear and hemolysis risk.
- The FDA accepted BiVACOR into TAP in August 2025, validating its regulatory path.
- Daniel Timms’ 2008 invention now has first-in-human implants at Baylor, Texas Heart, and UCSF.
Help us improve and share your feedback! Did you find this helpful?